Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma

• Status: Completed
• Trial end date: 2008-11-01

Summary

This is a pharmacogenic, prospective, and multicenter study in patients with advanced lung adenocarcinoma.

• Phase: N/A

Details

• Lead Sponsor: Spanish Lung Cancer Group
• Treatments: Cisplatin; Docetaxel; Erlotinib Hydrochloride; Gemcitabine